Iron-refractory iron deficiency anemia (IRIDA).
Study Goal
The researchers aimed to review the clinical features, genetic basis, and insights into systemic iron homeostasis provided by iron-refractory iron deficiency anemia (IRIDA).
Results Summary
The study found that IRIDA is caused by mutations in the TMPRSS6 gene, leading to iron deficiency anemia unresponsive to oral iron and only partially responsive to parenteral iron therapy. It highlights IRIDA as a distinct clinical entity affecting systemic iron regulation.
Population
Individuals with iron-refractory iron deficiency anemia (IRIDA), particularly those from affected kindreds.
Effective Dosage
Not specified
Duration
Not specified
Interactions
None mentioned
| Intervention | Direction | Endpoint | Population | Dosage | Impact | Claim # |
|---|---|---|---|---|---|---|
oral iron supplementation | no change | iron deficiency anemia | multiple family members in several kindreds | - | unresponsive | #1 |
parenteral iron therapy | no change | iron deficiency anemia | multiple family members in several kindreds | - | only partially responsive | #2 |
Iron deficiency anemia is a common global problem whose etiology is typically attributed to acquired inadequate dietary intake and/or chronic blood loss. However, in several kindreds multiple family members are affected with iron deficiency anemia that is unresponsive to oral iron supplementation and only partially responsive to parenteral iron therapy. The discovery that many of these cases harbor mutations in the TMPRSS6 gene led to the recognition that they represent a single clinical entity: iron-refractory iron deficiency anemia (IRIDA). This article reviews clinical features of IRIDA, recent genetic studies, and insights this disorder provides into the regulation of systemic iron homeostasis.